- Appili Therapeutics press release (OTCQB:APLIF): Q1 GAAP EPS of -C$0.01.
- As of June 30, 2023, the Company had cash of C$0.5 million, compared to C$2.5 million on March 31, 2023. In addition, the Company is dependent in large part on receiving the US$14 million DOD funding for the development of ATI-1701 in a timely manner.